Do analysts rate BYSI or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BLRX or ATYR?

aTyr Pharma has a consensus target price of $17.00, indicating a potential upside of 3,113.61%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Which has stronger valuation & earnings, BLRX or ATYR?

BioLineRx has higher revenue and earnings than aTyr Pharma. BioLineRx is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioLineRx $1.18M 10.07 -$1.17M -$1.92 N/A aTyr Pharma $190K 272.99 -$74.12M -$0.73 N/A

Is BLRX or ATYR more profitable?

aTyr Pharma has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% aTyr Pharma N/A -100.14% -73.55%

Do analysts recommend GOSS or BLRX?

Gossamer Bio currently has a consensus price target of $3.20, indicating a potential upside of 1,700.79%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Gossamer Bio is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GOSS or BLRX more profitable?

Gossamer Bio has a net margin of -324.82% compared to BioLineRx's net margin of -563.70%. Gossamer Bio's return on equity of 0.00% beat BioLineRx's return on equity. Company Net Margins Return on Equity Return on Assets Gossamer Bio -324.82% N/A -96.10% BioLineRx -563.70% -37.73% -19.42%

Do analysts recommend BLRX or EDSA?

Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 3.29%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Edesa Biotech is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is BLRX or EDSA more profitable?

Edesa Biotech has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% Edesa Biotech N/A -286.52% -75.36%

Do analysts recommend BLRX or MCRB?

Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 239.32%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

BioLineRx (BLRX) Competitors

$2.72 -0.04 (-1.45%)

Closing price 08/5/2026 03:59 PM Eastern

Extended Trading

$2.70 -0.02 (-0.74%)

As of 08/5/2026 07:34 PM Eastern

Compare

BLRX vs. BYSI, ATYR, GOSS, EDSA, and MCRB

Should you buy BioLineRx stock or one of its competitors? MarketBeat compares BioLineRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLineRx include BeyondSpring (BYSI), aTyr Pharma (ATYR), Gossamer Bio (GOSS), Edesa Biotech (EDSA), and Seres Therapeutics (MCRB).

How does BioLineRx compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

BeyondSpring has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BeyondSpring's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
BioLineRx	-563.70%	-37.73%	-19.42%

In the previous week, BeyondSpring's average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
BioLineRx	Neutral

BeyondSpring has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BeyondSpring has higher earnings, but lower revenue than BioLineRx. BeyondSpring is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	-$1.01M	-$0.14	N/A
BioLineRx	$1.18M	10.07	-$1.17M	-$1.92	N/A

Summary

BeyondSpring beats BioLineRx on 7 of the 10 factors compared between the two stocks.

How does BioLineRx compare to aTyr Pharma?

BioLineRx (NASDAQ:BLRX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, aTyr Pharma had 1 more articles in the media than BioLineRx. MarketBeat recorded 1 mentions for aTyr Pharma and 0 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score.

Company	Overall Sentiment
BioLineRx	Neutral
aTyr Pharma	Neutral

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioLineRx has higher revenue and earnings than aTyr Pharma. BioLineRx is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	10.07	-$1.17M	-$1.92	N/A
aTyr Pharma	$190K	272.99	-$74.12M	-$0.73	N/A

BioLineRx has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

aTyr Pharma has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
aTyr Pharma	N/A	-100.14%	-73.55%

aTyr Pharma has a consensus target price of $17.00, indicating a potential upside of 3,113.61%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Summary

aTyr Pharma beats BioLineRx on 11 of the 16 factors compared between the two stocks.

How does BioLineRx compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Gossamer Bio currently has a consensus price target of $3.20, indicating a potential upside of 1,700.79%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Gossamer Bio is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioLineRx has lower revenue, but higher earnings than Gossamer Bio. BioLineRx is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.86	-$170.37M	-$0.79	N/A
BioLineRx	$1.18M	10.07	-$1.17M	-$1.92	N/A

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gossamer Bio has a net margin of -324.82% compared to BioLineRx's net margin of -563.70%. Gossamer Bio's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
BioLineRx	-563.70%	-37.73%	-19.42%

In the previous week, Gossamer Bio had 4 more articles in the media than BioLineRx. MarketBeat recorded 4 mentions for Gossamer Bio and 0 mentions for BioLineRx. Gossamer Bio's average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company	Overall Sentiment
Gossamer Bio	Neutral
BioLineRx	Neutral

Gossamer Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Summary

Gossamer Bio beats BioLineRx on 12 of the 15 factors compared between the two stocks.

How does BioLineRx compare to Edesa Biotech?

BioLineRx (NASDAQ:BLRX) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 3.29%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Edesa Biotech is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Edesa Biotech has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Edesa Biotech	N/A	-286.52%	-75.36%

In the previous week, Edesa Biotech had 1 more articles in the media than BioLineRx. MarketBeat recorded 1 mentions for Edesa Biotech and 0 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.

Company	Overall Sentiment
BioLineRx	Neutral
Edesa Biotech	Neutral

BioLineRx has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	10.07	-$1.17M	-$1.92	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioLineRx has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Summary

Edesa Biotech beats BioLineRx on 9 of the 15 factors compared between the two stocks.

How does BioLineRx compare to Seres Therapeutics?

BioLineRx (NASDAQ:BLRX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 239.32%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Seres Therapeutics had 4 more articles in the media than BioLineRx. MarketBeat recorded 4 mentions for Seres Therapeutics and 0 mentions for BioLineRx. Seres Therapeutics' average media sentiment score of 0.75 beat BioLineRx's score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLineRx	Neutral
Seres Therapeutics	Positive

Seres Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Seres Therapeutics	N/A	-130.29%	-35.35%

BioLineRx has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

Seres Therapeutics has lower revenue, but higher earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	10.07	-$1.17M	-$1.92	N/A
Seres Therapeutics	$790K	61.39	$5.70M	-$5.17	N/A

Summary

Seres Therapeutics beats BioLineRx on 11 of the 16 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLRX vs. The Competition

Export

Metric	BioLineRx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.06M	$3.57B	$6.87B	$12.98B
Dividend Yield	N/A	3.76%	2.60%	9.79%
P/E Ratio	-1.42	7.68	280.35	25.27
Price / Sales	10.07	1,310.50	604.17	94.27
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	0.51	17.16	12.97	6.09
Net Income	-$1.17M	-$12.52M	$3.49B	$347.95M
7 Day Performance	0.74%	2.34%	2.41%	3.11%
1 Month Performance	-13.92%	-5.11%	-2.87%	-2.99%
1 Year Performance	-30.08%	52.15%	75.28%	20.51%

BioLineRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLRX BioLineRx	0.2464 of 5 stars	$2.72 -1.4%	N/A	-30.1%	$12.06M	$1.18M	N/A	40	Upcoming Earnings Gap Up
BYSI BeyondSpring	0.023 of 5 stars	$1.18 +0.9%	N/A	-52.4%	$48.52M	N/A	N/A	80	Upcoming Earnings Gap Up
ATYR aTyr Pharma	3.1336 of 5 stars	$0.49 +0.9%	$17.00 +3,341.3%	-89.9%	$48.44M	$190K	N/A	53
GOSS Gossamer Bio	2.1281 of 5 stars	$0.21 +2.9%	$3.20 +1,460.2%	-91.8%	$48.14M	$55.54M	N/A	180	Gap Up High Trading Volume
EDSA Edesa Biotech	0.8642 of 5 stars	$4.97 -7.1%	$5.00 +0.6%	+133.8%	$47.88M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLRX) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLineRx (BLRX) Competitors

BLRX vs. BYSI, ATYR, GOSS, EDSA, and MCRB

How does BioLineRx compare to BeyondSpring?

Summary

How does BioLineRx compare to aTyr Pharma?

Summary

How does BioLineRx compare to Gossamer Bio?

Summary

How does BioLineRx compare to Edesa Biotech?

Summary

How does BioLineRx compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLineRx (BLRX) Competitors

BLRX vs. BYSI, ATYR, GOSS, EDSA, and MCRB

How does BioLineRx compare to BeyondSpring?

Is BYSI or BLRX more profitable?

Does the media favor BYSI or BLRX?

Which has more risk & volatility, BYSI or BLRX?

Do analysts rate BYSI or BLRX?

Do institutionals & insiders hold more shares of BYSI or BLRX?

Which has higher earnings and valuation, BYSI or BLRX?

Summary

How does BioLineRx compare to aTyr Pharma?

Does the media refer more to BLRX or ATYR?

Do insiders & institutionals believe in BLRX or ATYR?

Which has stronger valuation & earnings, BLRX or ATYR?

Which has more volatility and risk, BLRX or ATYR?

Is BLRX or ATYR more profitable?

Do analysts prefer BLRX or ATYR?

Summary

How does BioLineRx compare to Gossamer Bio?

Do analysts recommend GOSS or BLRX?

Which has higher valuation & earnings, GOSS or BLRX?

Do insiders and institutionals believe in GOSS or BLRX?

Is GOSS or BLRX more profitable?

Does the media prefer GOSS or BLRX?

Which has more risk and volatility, GOSS or BLRX?

Summary

How does BioLineRx compare to Edesa Biotech?

Do analysts recommend BLRX or EDSA?

Is BLRX or EDSA more profitable?

Does the media favor BLRX or EDSA?

Which has better earnings and valuation, BLRX or EDSA?

Do institutionals & insiders have more ownership in BLRX or EDSA?

Which has more volatility and risk, BLRX or EDSA?

Summary

How does BioLineRx compare to Seres Therapeutics?

Do insiders & institutionals have more ownership in BLRX or MCRB?

Do analysts recommend BLRX or MCRB?

Does the media refer more to BLRX or MCRB?

Is BLRX or MCRB more profitable?

Which has more risk & volatility, BLRX or MCRB?

Which has higher earnings & valuation, BLRX or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools